Perspective Therapeutics, Inc. (NYSE:CATX) CFO Juan Graham Acquires 33,333 Shares

Perspective Therapeutics, Inc. (NYSE:CATX) CFO Juan Graham acquired 33,333 shares of the stock in a transaction on Friday, March 28th. The shares were purchased at an average price of $2.25 per share, for a total transaction of $74,999.25. Following the completion of the transaction, the chief financial officer now owns 35,354 shares in the company, valued at approximately $79,546.50. This represents a 1,649.33 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website.

Perspective Therapeutics Trading Down 8.0 %

CATX traded down $0.17 during midday trading on Tuesday, hitting $1.96. The company had a trading volume of 891,750 shares, compared to its average volume of 999,366. The firm’s 50-day simple moving average is $2.91 and its 200-day simple moving average is $6.19. Perspective Therapeutics, Inc. has a twelve month low of $1.91 and a twelve month high of $19.05.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Intech Investment Management LLC acquired a new stake in Perspective Therapeutics in the third quarter worth $137,000. Charles Schwab Investment Management Inc. increased its holdings in shares of Perspective Therapeutics by 221.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 433,522 shares of the company’s stock worth $5,788,000 after acquiring an additional 298,778 shares in the last quarter. The Manufacturers Life Insurance Company raised its position in shares of Perspective Therapeutics by 8.9% during the third quarter. The Manufacturers Life Insurance Company now owns 20,514 shares of the company’s stock worth $274,000 after purchasing an additional 1,672 shares during the period. FMR LLC lifted its holdings in shares of Perspective Therapeutics by 3,994.9% during the 3rd quarter. FMR LLC now owns 5,504,822 shares of the company’s stock valued at $73,489,000 after purchasing an additional 5,370,392 shares in the last quarter. Finally, BNP Paribas Financial Markets grew its position in shares of Perspective Therapeutics by 1,302.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 47,565 shares of the company’s stock valued at $635,000 after purchasing an additional 44,174 shares during the period. 54.66% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on CATX shares. Brookline Capital Management upgraded Perspective Therapeutics to a “strong-buy” rating in a report on Monday, March 10th. Lifesci Capital upgraded Perspective Therapeutics to a “strong-buy” rating in a report on Thursday, March 6th. Wedbush reissued an “outperform” rating and issued a $11.00 price target on shares of Perspective Therapeutics in a research note on Wednesday, March 26th. Cantor Fitzgerald raised shares of Perspective Therapeutics to a “strong-buy” rating in a research report on Tuesday, March 4th. Finally, Scotiabank initiated coverage on shares of Perspective Therapeutics in a report on Friday, March 7th. They set a “sector outperform” rating and a $15.00 price target on the stock. One equities research analyst has rated the stock with a hold rating, eight have issued a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $14.44.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.